- Home
- TTSH vs ENGN Comparison
TTSH vs ENGN Comparison
Compare TTSH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | TTSH | ENGN |
|---|---|---|
| Founded | 1985 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.3M | 379.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TTSH | ENGN |
|---|---|---|
| Price | $6.52 | $8.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.71 |
| AVG Volume (30 Days) | 178.0K | ★ 3.3M |
| Earning Date | 11-04-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $338,787,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.62 | $2.65 |
| 52 Week High | $7.75 | $11.14 |
Technical Indicators
Market Signals| Indicator | TTSH | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.98 | 54.28 |
| Support Level | $6.35 | $7.65 |
| Resistance Level | $6.57 | $8.29 |
| Average True Range (ATR) | 0.06 | 0.63 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 84.21 | 76.79 |
Price Performance
Historical ComparisonAbout TTSH Tile Shop Holdings Inc.
Tile Shop Holdings Inc is a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories in the United States. It manufactures its setting and maintenance materials, such as thinset, grout, and sealers. The company's primary market is retail sales to consumers, contractors, designers and home builders. Natural stone products include marble, travertine, granite, quartz, sandstone, slate, and onyx tiles. Man-made products include ceramic, porcelain, glass, cement, wood look, metal and luxury vinyl tile.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.